“A cross-sectional observational study to establish the association between ECOG performance status and age and administration of doublet or triplet chemotherapy containing Xeloda® (capecitabine) in advanced gastric cancer patients”, Eur J Oncol, vol. 18, no. 4, pp. 173–180, Jun. 2014, Accessed: Jul. 18, 2024. [Online]. Available: https://mattioli1885journals.com/index.php/EJOEH/article/view/2443